<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Primary Epstein-Barr virus (EBV) <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infection</z:e> is characterized by the presence of IgM antibodies to <z:mp ids='MP_0001799'>viral</z:mp> capsid antigen and the absence of antibodies to EB nuclear antigen </plain></SENT>
<SENT sid="1" pm="."><plain>Here, using a flow cytometry-based assay, we investigated whether IgA antibodies are a marker for <z:e sem="disease" ids="C0948192" disease_type="Disease or Syndrome" abbrv="">primary infection</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>Serum IgA antibodies in 15 individuals with primary <z:e sem="disease" ids="C0149678" disease_type="Disease or Syndrome" abbrv="">EBV infection</z:e> reacted with 15%-55.6% of HH514-16 Burkitt <z:hpo ids='HP_0002665'>lymphoma</z:hpo> cells expressing early lytic antigens (EAs), whereas IgA antibodies in serum samples from 15 healthy EBV-seropositive individuals reacted with 0.02%-2% of cells with EAs (P&lt;.0001) </plain></SENT>
<SENT sid="3" pm="."><plain>IgA antibodies in <z:e sem="disease" ids="C0948192" disease_type="Disease or Syndrome" abbrv="">primary infection</z:e> were directed against the Bam Z Epstein-Barr replication activator (ZEBRA) (BZLF1) and diffuse EA (BMRF1) EAs </plain></SENT>
<SENT sid="4" pm="."><plain>Thus, IgA antibodies to EBV EAs are produced during primary <z:e sem="disease" ids="C0149678" disease_type="Disease or Syndrome" abbrv="">EBV infection</z:e> and are likely to be stimulated as a result of lytic EBV replication in mucosal sites </plain></SENT>
<SENT sid="5" pm="."><plain>Detection of IgA antibodies to EA may be developed into a diagnostic tool for primary <z:e sem="disease" ids="C0149678" disease_type="Disease or Syndrome" abbrv="">EBV infection</z:e> </plain></SENT>
</text></document>